로딩 중...
52주 최고가 대비 58.9% 위치
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
SEC 13F 공시 기준 · 2025-Q4
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2022년 | 2023년 | 2024년 | 2025년 | 2026년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $2.16B | $2.36B | $2.75B | $3.20B |
| 영업이익 | - | $459.1M | $429.3M | $691.4M | $916.4M |
| 당기순이익 | - | $487.7M | $525.7M | $714.1M | $908.9M |
| 잉여현금흐름 (FCF) | - | $780.5M | $911.3M | $1.09B | $1.42B |
| 수익성 비율 | |||||
| 영업이익률 | - | 21.3% | 18.2% | 25.2% | 28.7% |
| 순이익률 | - | 22.6% | 22.2% | 26.0% | 28.4% |
| ROE (자기자본이익률) | - | 13.1% | 11.3% | 12.2% | 12.6% |
| ROA (자산이익률) | - | 10.2% | 8.9% | 9.7% | 10.1% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 9.7% | 16.2% | 16.3% |
| EPS 성장률 (YoY) | - | - | 7.3% | 34.2% | 25.9% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 55.2x | 70.0x | 51.9x | 33.5x |
| PBR (주가순자산배수) | - | 7.3x | 7.9x | 6.3x | 4.1x |
| PSR (주가매출배수) | - | 12.5x | 15.6x | 13.3x | 9.3x |
| FCF Yield | - | 2.9% | 2.5% | 3.0% | 4.8% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.02 | 0.01 | 0.01 | 0.01 |
| 유동비율 | - | 3.94 | 4.24 | 4.51 | 4.89 |
MOLINA HEALTHCARE INC
$179.86
$9.4B